Heparin coating in biodegradable ureteral stents does not decrease bacterial colonization-assessment in ureteral stricture endourological treatment in animal model

• Published in: Translational andrology and urology Vol. 10; no. 4; pp. 1700 - 1710
• Main Authors: Soria, Federico, de La Cruz, Julia E, Fernandez, Tomás, Budia, Alberto, Serrano, Álvaro, Sanchez-Margallo, Francisco M
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01-04-2021
• Subjects: Original; Biodegradable ureteral stent; ureteral sent; ureteral stricture (US); endoureterotomy; heparin coated
• ISSN: 2223-4691; 2223-4683; 2223-4691
• DOI: 10.21037/tau-21-19

We assessed an antireflux biodegradable heparin-coated ureteral stent (BraidStent
-H) in an animal model comparative study after endoscopic treatment of ureteral strictures.
A total of 24 female pigs underwent initial endoscopic, nephrosonographic, and contrast fluoroscopy assessment of the urinary tract. Afterward, unilateral laparoscopic ureteral stricture model was performed. Three weeks later, the animals underwent laser endoureterotomy and were randomly assigned to Group-I, in which a double-pigtail stent was placed for 6 weeks, or Group-II, in which a BraidStent®-H was placed. Follow-up was carried out by ultrasonography, contrast fluoroscopy, ureteroscopy, urinalysis and bacteriuria assessment at 3, 6, 12 and 5 months. Finally, a pathological study of the urinary system was performed.
There were no animals in Group-II with vesicoureteral reflux, with significance at 6 weeks with Group-I. Distal ureteral peristalsis was maintained in 50-75% in Group-II at 1-6 weeks. The 91.7% of stents in Group-II were degraded between 3-6 weeks, without obstructive fragments. Bacteriuria in Group II was 33.3-50% at 3 and 6 weeks. The global success rate by groups was 91.6% and 87.5% in groups I and II, respectively, with no statistical significance.
BraidStent
-H has been shown to be as efficacious as current ureteral stents in the treatment of benign ureteral strictures following laser endoureterotomy. In addition, it reduces the morbidity associated with current stents and has a homogeneous and predictable degradation rate of about 6 weeks, with no obstructive fragments. Future studies are required to improve the antibacterial coating to reduce BraidStent
-H contamination in view of the results obtained with the heparin coating.